Osteoclast differentiation inhibitor containing urolithin
AssigneeDaicel Corporation
InventorsKenji KOBATA, Sachie NAKATANI, Masatake KUDOH
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide an effective and highly safe agent for inhibiting osteoclast differentiation, and a food or drink, pharmaceutical, supplement, and cosmetic that produce an osteoclast differentiation-inhibiting effect; and the object is fulfilled by an agent for inhibiting osteoclast differentiation, comprising a urolithin.
Claims18
A method for inhibiting osteoclast differentiation, the method comprising:
- administering a composition to an individual having osteoporosis, the composition comprising urolithin that is 0.0001% to 10% by mass of the composition, and administered in an effective amount that reduces a number of the osteoclasts;
- and
- inhibiting differentiation of hematopoietic stem cells into osteoclasts in the individual.
A method for preventing or treating osteoporosis, the method comprising administering a prophylactically or therapeutically effective amount of a urolithin to a human.
Dependencies are inferred from the claim text.